Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus neoadjuvant chemotherapy vs neoadjuvant chemotherapy for locally advanced sinonasal carcinoma
ChiCTR2600124761Phase 2Not yet recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- May 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab in sinonasal carcinoma (2 arms), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoint: Objective Response Rate after neoadjuvant therapy. Planned start May 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
sinonasal carcinoma
Beyond the preview
Go deeper on ChiCTR2600124761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124761.